International Journal of Radiation Oncology * Biology * Physics
Volume 77, Issue 4 , Pages 969-973 , 15 July 2010

Reports of Unexpected Late Side Effects of Accelerated Partial Breast Irradiation—Radiobiological Considerations

  • Søren M. Bentzen, Ph.D., D.Sc.

      Affiliations

    • Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI
    • Corresponding Author InformationReprint requests to: Søren M. Bentzen, Ph.D., D.Sc., University of Wisconsin School of Medicine and Public Health, Department of Human Oncology, K4/316 Clinical Science Center, 600 Highland Avenue, Madison, WI 53792. Tel: (608) 265-8572; Fax: (608) 263-9947
    • ,
  • John R. Yarnold, M.D., FRCR.

      Affiliations

    • Section of Radiotherapy, Institute of Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom

Received 5 November 2009 ,Revised 29 January 2010 ,Accepted 31 January 2010.

References 

  1. Chen PY, Wallace M, Mitchell C, et al. Four-year efficacy, cosmesis, and toxicity using three-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. In press
  2. Hepel JT, Tokita M, Macausland SG, et al. Toxicity of three-dimensional conformal radiotherapy for accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2009;75:1290–1296
  3. Jagsi R, Ben-David MA, Moran JM, et al. Unacceptable cosmesis in a protocol investigating intensity-modulated radiotherapy with active breathing control for accelerated partial-breast irradiation. Int J Radiat Oncol Biol Phys. 2010;76:71–78
  4. Bentzen SM, Agrawal RK, Aird EG, et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: A randomised trial. Lancet Oncol. 2008;9:331–341
  5. Bentzen SM, Agrawal RK, Aird EG, et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: A randomised trial. Lancet. 2008;371:1098–1107
  6. Owen JR, Ashton A, Bliss JM, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: Long-term results of a randomised trial. Lancet Oncol. 2006;7:467–471
  7. Yarnold J, Ashton A, Bliss J, et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: Long-term results of a randomised trial. Radiother Oncol. 2005;75:9–17
  8. Whelan T, MacKenzie R, Julian J, et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst. 2002;94:1143–1150
  9. Marcial VA, Pajak TF, Chang C, et al. Hyperfractionated photon irradiation in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: Preliminary report by the Radiation Therapy Oncology Group (RTOG). Int J Radiat Oncol Biol Phys. 1985;13:41–47
  10. Cox JD, Pajak TF, Marcial VA, et al. ASTRO plenary: Interfraction interval is a major determinant of late effects, with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts: Results from Radiation Therapy Oncology Group 8313. Int J Radiat Oncol Biol Phys. 1991;20:1191–1195
  11. Bentzen SM, Ruifrok ACC, Thames HD. Repair capacity and kinetics for human mucosa and epithelial tumors in the head and neck: Clinical data on the effect of changing the time interval between multiple fractions per day in radiotherapy. Radiother Oncol. 1996;38:89–101
  12. Guttenberger R, Thames HD, Ang KK. Is the experience with CHART compatible with experimental data? A new model of repair kinetics and computer simulations. Radiother Oncol. 1992;25:280–286
  13. Turesson I, Notter G. Accelerated versus conventional fractionation. The degree of incomplete-repair in human skin with a four-hour-fraction interval studied after postmastectomy irradiation. Acta Oncol. 1988;27:169–179
  14. Nyman J, Turesson I. Does the interval between fractions matter in the range 4–8 h in radiotherapy? A study of acute and late human skin reactions. Radiother Oncol. 1995;34:171–178
  15. Turesson I, Thames HD. Repair capacity and kinetics of human skin during fractionated radiotherapy: Erythema, desquamation, and telangiectasia after 3 and 5 year's follow-up. Radiother Oncol. 1989;15:169–188
  16. Bentzen SM, Saunders MI, Dische S. Repair halftimes estimated from observations of treatment-related morbidity after CHART or conventional radiotherapy in head and neck cancer. Radiother Oncol. 1999;53:219–226
  17. Bentzen SM. Preventing or reducing late side effects of radiation therapy: Radiobiology meets molecular pathology. Nat Rev Cancer. 2006;6:702–713
  18. Bentzen SM, Thames HD, Overgaard M. Latent-time estimation for late cutaneous and subcutaneous radiation reactions in a single-follow-up clinical study. Radiother Oncol. 1989;15:267–274
  19. Brunt AM, Sydenham M, Bliss J, et al. A 5-fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the randomised UK FAST trial (ISRCTN62488883, CRUKE/04/015). EJC Supplements. 2009;7:2
  20. Bentzen SM, Overgaard M, Thames HD, et al. Early and late normal-tissue injury after postmastectomy radiotherapy alone or combined with chemotherapy. Int J Radiat Biol. 1989;56:711–715
  21. Bentzen SM, Skoczylas JZ, Overgaard M, Overgaard J. Radiotherapy-related lung fibrosis enhanced by tamoxifen. J Natl Cancer Inst. 1996;88:918–922
  22. Collette S, Collette L, Budiharto T, et al. Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: A study based on the EORTC Trial 22881-10882 “boost versus no boost”. Eur J Cancer. 2008;44:2587–2599
  23. Borger JH, Kemperman H, Smitt HS, et al. Dose and volume effects on fibrosis after breast conservation therapy. Int J Radiat Oncol Biol Phys. 1994;30:1073–1081
  24. Polgar C, Fodor J, Major T, et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast carcinoma—5-year results of a randomized trial. Int J Radiat Oncol Biol Phys. 2007;69:694–702
  25. Wazer DE, Kaufman S, Cuttino L, et al. Accelerated partial breast irradiation: an analysis of variables associated with late toxicity and long-term cosmetic outcome after high-dose-rate interstitial brachytherapy. Int J Radiat Oncol Biol Phys. 2006;64:489–495
  26. Bartelink H, Horiot JC, Poortmans PM, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007;25:3259–3265
  27. Al Uwini S, Antonini N, Poortmans PM, et al. The influence of the use of CT-planning on the irradiated boost volume in breast conserving treatment. Radiother Oncol. 2009;93:87–93
  28. Smith BD, Arthur DW, Buchholz TA, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys. 2009;74:987–1001
  29. Sauer R, Sautter-Bihl ML, Budach W, et al. Accelerated partial breast irradiation: Consensus statement of 3 German Oncology societies. Cancer. 2007;110:1187–1194

 Conflict of interest: none.

PII: S0360-3016(10)00234-8

doi: 10.1016/j.ijrobp.2010.01.059

International Journal of Radiation Oncology * Biology * Physics
Volume 77, Issue 4 , Pages 969-973 , 15 July 2010

Article Tools